The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program. Pharmacodynamic effects of apremilast on plasma b...

Descripción completa

Detalles Bibliográficos
Autores principales: Schafer, Peter H., Chen, Peng, Fang, Lorraine, Wang, Andrew, Chopra, Rajesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417944/
https://www.ncbi.nlm.nih.gov/pubmed/25973439
http://dx.doi.org/10.1155/2015/906349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417944/
https://www.ncbi.nlm.nih.gov/pubmed/25973439
http://dx.doi.org/10.1155/2015/906349

Ejemplares similares